Scientific Evidence

IDgenetix-Guided Medication Management for Major Depressive Disorder: Confirmation of Randomized Controlled Trial Outcomes by Real-World Evidence

Nov 2023

This study compared the clinical outcome results from Bradley et al. (2018) with real-world evidence. Patient response and remission rates strongly aligned between both studies.

Author: Cao F, Hanson A, Cook R

Publication: Poster at NEI Congress 2023

The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients With Major Depressive Disorder in a Randomized Controlled Trial.

Sep 2023

In this study, drug-drug interactions accounted for 32% of all IDgenetix-guided drug recommendations, and lifestyle factors accounted for 11%. Incorporating these non-genetic factors in IDgenetix testing significantly impacts the number of drug recommendations and improves remission rates in patients with moderate to severe depression.

Author: Cao F, Hanson A, Cook R, et al.

Publication: Poster at Psych Congress 2023

Improved response and remission rates in patients receiving IDgenetix-guided medication management for major depressive disorder

May 2023

In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in remission compared to patients whose medication was not guided by the test

Author: Cao F, Maciel A, Wosnik K, et al.

Publication: Poster at 2023 American Psychiatric Association (APA) Annual Meeting

Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis

Mar 2023

Pharmacogenomic (PGx) testing may increase the probability of remission and response in patients with major depressive disorder (MDD) undergoing pharmacotherapy.

Author: Bunka M, et al.

Publication: Psychiatry Res

Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomized controlled trials

Jan 2023

Major depressive disorders are prevalent conditions with limited treatment response and remission. Pharmacogenomics tests including CYP2D6 and CYP2C19 genomic variants provide the most reliable actionable approach to guide choice and dosing of antidepressants in major depression to improve outcomes.

Author: Arnone D, et al.

Publication: Neuroscience & Behavioral Reviews

Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials

Sep 2022

IDgenetix-guided therapy demonstrated the most significant efficacy improvement of all​. IDgenetix was 2.65 times more likely to achieve remission vs. control, and had the highest risk ratio of the 4 RCTs with positive outcomes.

Author: Brown L, et al.

Publication: Clinical Pharmacology & Therapeutics

Efficacy and tolerability of therapies set under pharmacogenetic tools suggestions: A systematic review with meta-analysis about mood disorders

May 2022

This systematic review with meta-analysis aims to evaluate the utility of pharmacogenetic tests (PGT) in terms of efficacy and tolerability into the routine clinical treatment of mood disorders.

Author: Ielmini M, et al.

Publication: Psychiatry Res

The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis

Dec 2018

Author: Rosenblat, et al.

Publication: J Affective Disorders

Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder

Aug 2018

Recent clinical trials indicate that pharmacogenetic-guided treatment of major depressive disorder (MDD) results in higher treatment response rates by genetically matching patients to medications and avoiding a trial-and-error process.

Author: Groessl E, et al.

Publication: J Manag Care Spec Pharm

Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings

Jan 2018

Our study utilizes published health care costs and clinical patient outcome data to model the economic impact of pharmacogenetic-guided treatment for depression in a variety of clinical settings.

Author: Maciel A, et al.

Publication: Neuropsychiatr Dis Treat

Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility

Jan 2018

The objective of this study was to evaluate the effect of pharmacogenetics-guided treatment on patients diagnosed with depression and/or anxiety, in a diverse set of clinical settings, as compared to the standard of care.

Author: Bradley, et al.

Publication: J Psychiatr Res

Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety

Nov 2017

IDgenetix, a novel pharmacogenomic test, has been shown to improve outcomes by predicting the likelihood of response to different psychotherapeutic medications.

Author: Najafzadeh M, et al.

Publication: Pharmacoeconomics